title: Investigation of the mechanism of action of 2% fusidic acid lotion in the treatment of acne vulgaris.
abstract: We describe the results of a single-centre, double-blind, vehicle-controlled, parallel group study on the quantitative effects of 2% fusidic acid lotion (Fucidin lotion) in facial acne vulgaris. The trial was completed by 52 patients aged 15-25 years with mild to moderate acne who had been randomized to either Fucidin Lotion (n = 25) or its base (n = 27). Primary outcome measures included colony counts of Propionibacterium acnes and micrococcaceae and measurements of skin surface lipid free fatty acids and sebum excretion rate. Clinical assessment was based on the acne grade, count of inflamed and non-inflamed lesions and evidence of a primary irritant dermatitis. There was a variable but gradual reduction in lesion counts with the maximum improvement at 12 weeks for inflamed lesions, where the reduction was 19.9% for fusidic acid and 24.7% for the placebo. The non-inflamed lesions decreased by 10.8% in the fusidic acid group and increased by 15.9% in the placebo group; this difference was not statistically significant. Although the fusidic acid reduced the micrococcaceae count by 1 log cycle, inferring adequate compliance, there was no reduction in the counts of P. acnes, surface free fatty acids or sebum excretion rate. This study has failed to explain the mechanism of action of topical fusidic acid.
authors.affiliation: Department of Dermatology, Leeds General Infirmary.
authors.forename: S
authors.initials: S
authors.lastname: Sommer
authors.forename: R
authors.initials: R
authors.lastname: Bojar
authors.forename: W J
authors.initials: WJ
authors.lastname: Cunliffe
authors.forename: D
authors.initials: D
authors.lastname: Holland
authors.forename: K T
authors.initials: KT
authors.lastname: Holland
authors.forename: H
authors.initials: H
authors.lastname: Naags
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000382:microbiology; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D005230:Fatty Acids, Nonesterified / Q000032:analysis; D005260:Female; D005672:Fusidic Acid / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011425:Propionibacterium acnes / Q000302:isolation & purification; D012867:Skin / Q000737:chemistry; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D005230:Fatty Acids, Nonesterified; D005672:Fusidic Acid